Select your country
Select a country to go to the website of the respective STADA sales company.
Czech Republic (2)
Saudi Arabia (1)
The Phillippines (1)
United Arab Emirates (1)
United Kingdom (3)
Alvotech and STADA enter into a strategic collaboration for seven biosimilar candidates in Europe
to become a major player in these branded markets
A leading Consumer Healthcare company in Central Europe
STADA Health Report 2019
Opt-out solution would double number of organ donors in Germany
STADA's Movymia® is a cost-effective alternative to Forsteo®.
With reported sales growth of 11 percent in the first-half of 2019, STADA is performing well above the industry average.
49 percent of Germans have experienced a burnout, have felt like were on the verge of it or know the symptoms from personal experience.
How sensible are prescription requirements for contraceptive or potency pills?
From a local pharmaceutical company into one of the leading pharmaceutical companies in Vietnam.
Only 46 percent of Germans say they cook fresh meals almost every day. In Italy, this applies to 79 percent.
Especially women and young people often keep an eye out for their neighbours at the beach.
As of September 15, 2019, Eelco Ockers will strengthen the worldwide STADA Executive Committee
He joins from Teva Italy, where he was leading the Generics and OTC business.
Strengthening of skin care business in Europe
STADA and Xbrane strengthen collaboration
STADA launches generic Bortezomib in 14 European countries
Half of Europeans are ready for Dr Robot and treatments via webcam
The path is clear for Exforge generics
In 2018, the majority of STADA’s top markets showed positive sales development, both in generics and consumer health.
Following the takeover by financial investors, the pharmaceutical manufacturer STADA intends to expand its business considerably.